Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An update from Neurometrix ( (NURO) ) is now available.
NeuroMetrix, Inc. has entered into a merger agreement with electroCore, Inc., where NeuroMetrix will become a wholly owned subsidiary of electroCore. Under the terms of the merger, NeuroMetrix shareholders will receive cash and contingent value rights (CVRs) based on net cash balance and potential future proceeds from divesting the DPNCheck platform and sales of Quell products. This merger is expected to enhance patient access to Quell technology through electroCore’s commercial channels, while the DPNCheck platform is anticipated to be divested to continue benefiting patients with its diagnostic capabilities.
More about Neurometrix
NeuroMetrix is a commercial stage healthcare company specializing in neurotechnology devices aimed at addressing chronic pain and diabetes markets. The company offers wearable and handheld medical devices supported by proprietary consumables and software solutions, including mobile apps, enterprise software, and cloud-based systems. Its primary products include the Quell® wearable neuromodulation platform and the DPNCheck® point-of-care screening test for peripheral neuropathy.
YTD Price Performance: 8.33%
Average Trading Volume: 16,811
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $7.97M
See more insights into NURO stock on TipRanks’ Stock Analysis page.
